Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study

• DOI: 10.1038/srep42499
• Publication Date: 2017-02-13T10:17:57Z
• Authors: Andrea Casadei Ga...; Flavia Foca; Mario Scartozzi; Nicola Silvestris; Emiliano Tamburini; Luca Faloppi; Oronzo Brunetti; Britt Rudnas; Salvatore Pisconti; Martina Valgiusti; Giorgia Marisi; Francesco Giusepp...; Giorgio Ercolani; Davide Tassinari; Stefano Cascinu; Giovanni Luca Fra...
• Keywords: Adult; Male; 0301 basic medicine; Administration; Metronomic; Adult; Aged; Aged; 80 and over; Antimetabolites; Antineoplastic; Capecitabine; Carcinoma; Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Retreatment; Retrospective Studies; Treatment Outcome; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Antimetabolites; Article; 03 medical and health sciences; Retrospective Studie; 80 and over; Humans; Metronomic; Capecitabine; Aged; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Aged, 80 and over; Multidisciplinary; Carcinoma; Liver Neoplasms; capecitabina, hepatocellular carcinoma, best supportive care; Hepatocellular; Middle Aged; Antineoplastic; Combined Modality Therapy; 3. Good health; Treatment Outcome; Liver Neoplasm; Administration; Administration, Metronomic; Retreatment; Proportional Hazards Model; Female; Human

Abstract Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety efficacy metronomic as second-line treatment. This multicentric analyzed data patients unresponsive or intolerant sorafenib treatment with best supportive care (BSC).Median progression free survival 3.1 months treated (95%CI: 2.7–3.5). Median overall 12.0 (95% CI: 10.7–15.8) receiving capecitabine, while 9.0 6.5–13.9) BSC. result univariate unweighted Cox regression model shows a 46% reduction death risk for on 0.357–0.829; p =0.005) compared BSC alone. After weighting potential confounders, remained essentially unaltered (45%; 95%CI: 0.354–0.883; = 0.013). Metronomic seems terms management adverse events, showing anti-tumour activity which needs further evaluation phase III studies.